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Abstract
Aim: To investigate the effect of a novel enamel matrix derivative formulation (EMD- 
liquid or Osteogain) combined with an absorbable collagen sponge (ACS) on periodon-
tal wound healing in intra- bony defects in monkeys.
Materials and Methods: Chronic two- wall intra- bony defects were created at the dis-
tal aspect of eight teeth in three monkeys (Macaca fascicularis). The 24 defects were 
randomly assigned to one of the following treatments: (i) open flap debridement 
(OFD) + ACS alone, (ii) OFD + Emdogain + ACS (Emdogain/ACS), (iii) OFD + Osteogain 
+ ACS (Osteogain/ACS) or (iv) OFD alone. At 4 months, the animals were euthanized 
for histologic evaluation.
Results: Osteogain/ACS resulted in more consistent formation of cementum, perio-
dontal ligament and bone with limited epithelial proliferation compared to OFD alone, 
Emdogain/ACS and OFD + ACS. Among the four treatment groups, the Osteogain/
ACS group demonstrated the highest amount of regenerated tissues. However, com-
plete periodontal regeneration was not observed in any of the defects in the four 
groups.
Conclusions: The present findings indicate that in two- wall intra- bony defects, recon-
structive surgery with Osteogain/ACS appears to be a promising novel approach for 
facilitating periodontal wound healing/regeneration, thus warranting further clinical 
testing.
K E Y W O R D S
animal study, carrier, enamel matrix proteins, intra-bony defect, periodontal regeneration
1  | INTRODUCTION
It has been demonstrated that the application of an enamel matrix 
derivative (EMD) substantially facilitates periodontal wound healing/
regeneration including clinical attachment gain and pocket depth re-
duction for over 20 years (Hammarström, Heijl, & Gestrelius, 1997; 
Heijl, Heden, Svärdström, & Östgren, 1997; Mellonig, 1999; Miron, 
Sculean, et al., 2016; Sculean, Alesandri, Miron, Salvi, & Bosshardt, 
2011). The viscous consistency of EMD (Emdogain) may limit its 
space- making potential and subsequently affect the outcomes in 
cases where flap collapse due to unfavourable defect anatomy may 
occur (Cochran et al., 2003; Lekovic et al., 2000; Mellonig, 1999; 
Tonetti, Pini- Prato, & Cortellini, 1993). The combination of Emdogain 
with various grafting materials is one approach to treat non- contained 
intra- bony defects and aims at preventing flap collapse and, at the 
same time, promoting the regeneration process (Lekovic et al., 2000; 
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Cochran et al., 2003; Sculean et al., 2003; Sculean, Pietruska, Arweiler, 
Auschill, & Nemcovsky, 2007; Shirakata et al., 2007; Yamamoto, 
Masuda, Shibukawa, & Yamada, 2007; Gurinsky, Mills, & Mellonig, 
2004; Velasquez- Plata, Scheyer, & Mellonig, 2002; Jepsen et al., 2008; 
Bokan, Bill, & Schlagenhauf, 2006; Kuru, Yilmaz, Argin, & Noyan, 2006; 
Trombelli & Farina, 2008; Yilmaz, Cakar, Yildirim, & Sculean, 2010).  A 
recent systematic review found that the combination of Emdogain 
with a bone grafting material led to significantly higher clinical at-
tachment level gains and probing depth reductions compared with 
Emdogain alone (Matarasso et al., 2015). On the other hand, other 
studies have failed to reveal adjunctive effects of a combination ther-
apy especially in cases where alloplastic materials were used in combi-
nation with Emdogain (Bokan et al., 2006; Jepsen et al., 2008). Despite 
the fact that the potential influence of the chosen grafting material on 
the clinical outcomes has been previously discussed, the reasons for 
this variability are still unclear (Miron, Guillemette, Zhang, Chandad, & 
Sculean, 2014; Tu, Woolston, & Faggison, 2010).
Recently, in an attempt to characterize protein adsorption of 
enamel matrix proteins (EMPs) to bone grafts, large variability between 
commonly utilized bone grafting materials including a bovine- derived 
natural bone mineral (NBM), demineralized freeze dried bone allograft 
(DFDBA) and a synthetic calcium phosphate was reported (Miron 
et al., 2015). More importantly, it was found that a liquid formula-
tion of EMD markedly improved protein adsorption when compared 
to Emdogain (Miron et al., 2015). Further advantages include better 
surface coating and penetration of EMPs within the bone biomateri-
als capable of gradual release of EMPs over time (Miron et al., 2015). 
These prominent findings led to the development of a new liquid car-
rier system for EMD (EMD- liquid: Osteogain) specifically designed for 
mixing with bone grafting materials.
In this respect, it has been reported that the fast resorption of re-
sidual bone grafts is desirable to avoid the risk for infection and to 
increase the amount of regenerated tissues in bone/periodontal de-
fects (MacNeill, Cobb, Rapley, Glaros, & Spencer, 1999; Potijanyakul, 
Sattayasansakul, Pongpanich, Leepong, & Kintarak, 2010; Shirakata 
et al., 2002, 2007; Yoshinuma, Sato, Fukuyama, Murai, & Ito, 2012). 
Moreover, when discussing the use of bone grafting materials in regen-
erative periodontal surgery, it has to be kept in mind that histologically, 
the healing following bone grafting is frequently accompanied by per-
sistence of grafting residues surrounded by either bone or connective 
tissue (Ivanovic, Nikou, Miron, Nikolidakis, & Sculean, 2014; Sculean 
et al., 2015). Therefore, the biological rationale for using grafting ma-
terials to obtain periodontal regeneration needs to be questioned 
while, at the same time, the use of completely bioresorbable materials 
such as collagen matrices/scaffolds may represent a realistic alterna-
tive to act both as carriers for biologics and for stabilizing the wound 
(Stähli, Miron, Bosshardt, Sculean, & Gruber, 2016; Susin et al., 2015). 
Due to its high clinical applicability, biocompatibility and uneventful 
biodegradation in bone and periodontal surgeries, an absorbable col-
lagen sponge (ACS) has been extensively tested as a putative scaffold 
or carrier (Cochran, Jones, Lilly, Fiorellini, & Howell, 2000; Kim et al., 
2013; McPherson, 1992; Yamashita et al., 2010). Practically, ACSs are 
a relatively low- cost FDA- approved product composed mainly of type 
I collagen. Type I collagen is also the major organic component of bone 
extracellular matrix, and several studies have reported that collagen 
application facilitated osteoblastic differentiation, the expression of 
various osteogenic markers and bone formation (Donzelli et al., 2007; 
Mizuno et al., 1997; Shimoji et al., 2009; Talley- Ronsholdt, Lajiness, & 
Nagodawithana, 1995; Yamanouchi et al., 2001). Furthermore, colla-
gen products have the ability to adsorb extracellular matrix molecules 
(e.g. laminin and fibronectin) and growth factors responsible for in-
creasing cell migration and/or proliferation (Itoh, Aso, Furuse, Noishiki, 
& Miyata, 2001; Miron, Fujioka- Kobayashi, Zhang, Sculean, et al., 
2016; Shirakata et al., 2017; Stähli et al., 2016).
A very recent animal study has evaluated the effect of a novel liq-
uid carrier system of EMD (Osteogain) soaked with an ACS (Osteogain/
ACS) upon periodontal wound healing/regeneration in class III furca-
tion defects in monkeys (Shirakata et al., 2017). The findings revealed 
for the first time that Osteogain/ACS possessed favourable physico-
chemical properties facilitating adsorption of amelogenin onto ACS 
and additionally enhanced periodontal wound healing/regeneration of 
furcation defects when compared to Emdogain/ACS (Shirakata et al., 
2017).
However, at present, no data have evaluated the potential effects 
of Osteogain/ACS in promoting periodontal wound healing/regenera-
tion in intra- bony defects. Thus, the aim of this study was to investi-
gate the potential effects of Osteogain in combination with an ACS on 
periodontal regeneration in two- wall intra- bony defects in non- human 
primates.
2  | MATERIALS AND METHODS
2.1 | Experimental animals
Three 7- to 8- year- old male monkeys (Macaca fascicularis), weigh-
ing 6.91–7.02 kg, were selected for this study. The animals ex-
hibited intact dentition with healthy periodontium. All procedures 
during the in life phase for 9 months (from 6 November 2014 to 
Clinical Relevance
Scientific rationale for the study: The potential effect of a new 
liquid formulation of EMD (Osteogain) combined with an 
absorbable collagen sponge (ACS) on periodontal wound 
healing/regeneration in two- wall intra- bony defects is at 
present unknown.
Principal findings: Treatment of intra- bony defects with OFD 
and Osteogain/ACS enhanced periodontal wound healing/
regeneration more consistently than treatment with 
OFD + ACS, OFD + Emdogain/ACS or OFD alone.
Practical implications: The present findings provide for the 
first time histologic support for the biological potential of 
Osteogain/ACS to promoting periodontal regeneration in 
two- wall intra- bony defects.
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3 August 2015) were approved by the ethical committee of the 
Animal Research Center of Kagoshima University, Japan (approval 
no. D14026).
2.2 | Enamel matrix derivative and biomaterial
Emdogain (EMPs and propylene glycol alginate) and Osteogain (EMPs 
in acetic acid) (0.3- ml vials, working concentration 30 mg/ml) were 
kindly provided by Straumann AG, Basel, Switzerland. The native type 
I and III porcine ACS (Collacone®; Botiss, Berlin, Germany) was utilized 
as a candidate material with the ability to efficiently adsorb growth 
factors due to its three- dimensional structure.
2.3 | Preparation of experimental two- wall intra- 
bony defects
One experienced surgeon (Y.S) performed all surgical procedures 
under general and local anaesthesia using aseptic routines. General 
anaesthesia was achieved with ketamine hydrochloride (0.2 ml/kg 
IM)/medetomidine hydrochloride (0.08 ml/kg IM) in combination with 
maintained spontaneous breathing. Local anaesthesia was performed 
using lidocaine HCl/epinephrine (2%, 1:80,000; Xylocaine).
Two months prior to the start of the experiment, the mandibular 
and maxillary second pre- molars and lateral incisors were extracted to 
provide enough space for defect creation. Following elevation of mu-
coperiosteal flaps, two- wall intra- bony defects with a depth of 5 mm 
measured from the bone crest were produced by means of a slowly 
rotating round and fissure burs with a sterile saline coolant at the distal 
surfaces of both maxillary and mandibular first pre- molars and central 
incisors (i.e. 24 defects in total) according to a previously described 
protocol (Sculean, Donos, Brecx, Reich, & Karring, 2000a). To prevent 
spontaneous healing and induce plaque accumulation, ligature wires 
were placed into the intra- bony defects (Figure 1a). The flaps were 
repositioned and stabilized with 4–0 silk sutures. Ten days following 
surgery, the sutures were removed. For the first 2 months follow-
ing the first surgery, no oral hygiene measures were performed and 
the animals were fed a soft diet. After removal of the ligature wires, 
a plaque control programme was resumed including routine flushing 
(three times a week) of the oral cavity with a chlorhexidine solution 
(chlorhexidine gluconate; 25 ml of a 2% solution) for 4 weeks.
2.4 | Reconstructive surgery
At 12 weeks following the defect creation (Figure 1b), intra- sulcular 
incisions were performed and full- thickness buccal and lingual mu-
coperiosteal flaps were elevated to expose the intra- bony defects 
(Figure 1c). All granulation tissue was removed, and the exposed 
root surface was carefully scaled and planed (Figure 1d). Cementum 
was removed using Gracey curettes and a chisel. Reference notches 
were made using a #1 round bur on the root surface at the base of 
the defects, and at the cemento- enamel junction (CEJ) for histomet-
ric analysis, and on the crown surface to indicate the precise centre 
plane of the two- wall intra- bony defects and to aid in optimal his-
tologic processing. Two- wall intra- bony defects were randomly as-
signed to one of the following treatments: ACS alone, Emdogain with 
ACS (Emdogain/ACS), Osteogain with ACS (Osteogain/ACS) and open 
flap debridement (OFD) as a surgical control. In the ACS group, ACS 
was mixed with sterile saline before being applied to the defect. The 
root surfaces at the experimental defects that received Emdogain 
or Osteogain were conditioned with a 24% EDTA gel (PrefGel®; 
Straumann AG) for 2 min and then, along with the adjacent muco-
periosteal flaps, thoroughly rinsed with sterile saline to remove EDTA 
residues. Prior to the placement of Emdogain/ACS or Osteogain/
ACS, the ACS was fully saturated with Emdogain or Osteogain and 
the constructs were allowed to rest for 10 min. The constructs were 
then filled in the defect close to the residual bone crest (Figure 1e,f). 
A periosteal releasing incision was made to allow tension- free coronal 
repositioning of the flap, followed by suturing (Gore- Tex CV- 6 Suture, 
F IGURE  1 Clinical appearance of the maxillary buccal aspect of Macaca fascicularis. (a) Induction of chronic inflammation. After fabrication of 
the two- wall intra- bony defects, plaque- retentive ligatures were placed to encourage growth of oral microflora along the exposed root surfaces. 
(b) Prior to reconstructive surgery. (c) Immediately after flap reflection. Note the excessive bone resorption in the chronic defects. (d) Defects 
were exposed and debrided again at the time of reconstructive surgery. (e) Osteogain/ACS construct was placed into the defect; (f) Emdogain/
ACS construct was placed into the defect; (g) flaps were coronally repositioned and sutured. (h) 16 weeks after reconstructive surgery
(a)
(e)
(b)
(f)
(c)
(g)
(d)
(h)
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W. L; Gore & Associates Inc., Flagstaff, AZ, USA) slightly coronal to 
the CEJ (Figure 1g).
2.5 | Postsurgical protocol
After the operation, the animals received a single dose of intramus-
cularly administered antibiotics. The sutures were removed after 
14 days of healing, and postoperative plaque control was main-
tained by routine flushing (three times a week) of the oral cavity 
with a chlorhexidine solution (chlorhexidine gluconate; 25 ml of 
a 2% solution). Then, 4 months after the reconstructive surgery 
(Figure 1h), the animals were euthanized by an overdose injection 
of sodium thiopental.
2.6 | Histologic processing
All the defects, including the experimental and control sites, were then 
dissected free along with the surrounding soft and hard tissues. The 
tissue blocks were fixed in 10% buffered formalin, trimmed and rinsed 
in phosphate- buffered saline. These samples were then analysed 
using a micro- computed tomography system (Scan Xmate- E080®; 
Comscantecno Corporation., Kanagawa, Japan) and software (TRI/3D 
VIEWER; Ratoc System Engineering Co., Ltd, Tokyo, Japan) for ob-
serving bucco- lingual appearances (including defect margin and root 
location in the alveolar bone) and for discerning the central portion 
of the defects to obtain the optimal histologic sections. The samples 
were decalcified, dehydrated and embedded in paraffin. Step serial 
sections of 6 μm thickness were then prepared along the mesio- distal 
plane, stained with haematoxylin/eosin or with Azan- Mallory at inter-
vals of 90 μm.
2.7 | Histometric analysis
All the specimens were analysed histometrically under a light micro-
scope (BX51; Olympus Corp., Tokyo, Japan) equipped with a com-
puterized image system (cellSens, Olympus Corp). For histometric 
analysis, three sections approximately 90 μm apart were selected 
from the most central area of each two- wall defects, identified by the 
length of the root canal and the reference notches. The mean value 
of each histometric parameter was then calculated for each site. The 
following parameters were measured by the same experienced and 
masked examiner (T. N). Intra- examiner reproducibility was ensured 
by reading 24 sections from all sites by the examiner and repeating 
the same procedure 48 hr later. Calibration was accepted at the 90% 
level.
• Defect height (DH): the distance between the apical extent of root 
planing and CEJ.
• Apical extension of the junctional epithelium (JE): distance between 
apical extension of JE and CEJ.
• Connective tissue adhesion (CT; without cementum): distance 
between apical extent of JE and coronal extent of newly formed 
cementum.
• New bone formation (NB): distance between apical extent of root 
planing and coronal extent of newly formed alveolar bone along the 
root surface.
• New cementum formation (NC): distance between apical extent of 
root planing and coronal extent of newly formed cementum on de-
nuded root surface.
• New attachment formation (NA): total linear length of the root sur-
face covered by NC adjacent to newly formed bone, with function-
ally oriented collagen fibres;
Linear measurements, except for DH, were also expressed as the 
percentage of the DH within each defect.
3  | RESULTS
3.1 | Clinical observations
All surgical treatments were well tolerated by the animals, and clini-
cal healing was uneventful at all 24 sites with limited signs of inflam-
mation and limited gingival recession. No adverse reactions including 
material exposure, increased tooth mobility, infection and suppuration 
were observed throughout the entire experimental period.
3.2 | Histologic observations
3.2.1 | OFD group
The healing pattern in the OFD group was characterized by extensive 
collapse of the flap, resorption of the parent bone crest and limited 
periodontal regeneration (Figure 2a). Considerable apical migration of 
the JE was observed. Thick new cellular cementum with or without 
collagen fibres obliquely to the root surface was detected in the lower 
portion of the defect (Figure 2b). NB formation with narrow bone 
growth parallel to the root surface occurred to a varying extent. In 
one defect, a slight ankylosis was found in the apical area of the notch. 
Connective tissue fibres were observed aligned parallel to or detached 
from the denuded root surface (Figure 2c).
3.2.2 | ACS group
In the ACS- applied sites, apical extension of the JE was more sup-
pressed than in the OFD group. Newly formed bone was observed 
along and around the root surface (Figure 3a). Thick new cellular 
cementum with or without inserting collagen fibres was detected in 
the middle portion of the defect (Figure 3b). The collagen fibres ap-
peared to be sparser than those observed in the Emdogain/ACS and 
Osteogain/ACS groups (Figure 3c).
3.2.3 | Emdogain/ACS group
Three of six sites in the Emdogain/ACS group healed well with robust 
periodontal regeneration (Figure 4a). A continuous layer of new mixed 
acellular/cellular cementum was observed on the previously denuded 
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root surface. Dense collagen fibres were seen inserting into the newly 
formed cementum, obliquely oriented to the root surface (Figure 4b). 
Bone formation was noted extending from the parent bone crest to-
wards the coronal region of the defect (Figure 4a). However, in three 
samples, periodontal regeneration was modest or limited to the apical 
half of the defects (Figure 4c). The area of connective tissue adjacent 
to the root surface without cementum formation was broad and var-
ied more in the Emdogain/ACS- treated sites than in the other groups 
(Figure 4c,d).
3.2.4 | Osteogain/ACS group
In this group, NC with perpendicularly inserting collagen fibres was con-
sistently observed. Cellular intrinsic fibre cementum was mostly found 
at the apical portion and tended to change to acellular extrinsic fibre 
cementum towards the coronal portion of the denuded root surface 
(Figures 5b and 6b,c). Bone formation was noted extending from the 
parent bone crest towards the coronal region of the defect (Figures 5a 
and 6a). The newly formed periodontal ligament was highly vascularized 
F IGURE  2 Representative photomicrographs of a two- wall intra- bony defects treated with open flap debridement (OFD). (a) Overview. 
(Bar: 1 mm; Azan- Mallory staining) (b) Higher magnification of the apical framed area in (a) (Bar: 200 μm; Azan- Mallory staining). (c) Higher 
magnification of the coronal framed area in (a) (Bar: 200 μm; Azan- Mallory staining). NB, new bone; NC, new cementum; PDL, periodontal 
ligament; JE, junctional epithelium; CT, connective tissue; N, notch (apical extent of root planing); D, root dentin
(a) (b) (c)
F IGURE  3 Representative photomicrographs of a two- wall intra- bony defects treated with ACS. (a) Overview. (Bar: 1 mm; Azan- Mallory 
staining). (b) Higher magnification of the apical framed area in (a). (c) Higher magnification of the coronal framed area in (a). (Bar: 100 μm; Azan- 
Mallory staining). NB, new bone; NC, new cementum; PDL, periodontal ligament; N, notch (apical extent of root planing); D, root dentin
(a) (b) (c)
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and tightly confined between the newly formed cementum and bone, 
maintaining its width up to the coronal portion (Figures 5 and 6).
Absorbable collagen sponge appeared to be completely resorbed 
after 16 weeks of healing in the ACS, Emdogain/ACS and Osteogain/
ACS groups. There was no extensive root resorption or ankylosis in 
these treatment groups.
3.3 | Histometric analysis
The results of the histometric analysis are summarized in Table 1. 
The length of JE observed in the Osteogain/ACS (3.18 ± 1.34 mm) 
group was shorter than those in the OFD (4.57 ± 0.98 mm), ACS 
(3.63 ± 1.13 mm) and Emdogain/ACS (3.76 ± 1.58 mm) groups. 
The amount of CT (without cementum) in the Emdogain/ACS 
(1.00 ± 1.33 mm) group was greater than in the OFD (0.45 ± 0.42 mm), 
ACS (0.80 ± 0.67 mm) and Osteogain/ACS (0.56 ± 0.78 mm) groups. 
The Osteogain/ACS group showed the greatest amount of NB 
among the groups examined. The amounts of NC and NA formation 
in the Osteogain/ACS (4.00 ± 1.49 mm, 3.59 ± 1.65 mm) group were 
greater compared to the OFD (3.21 ± 1.60 mm, 1.49 ± 0.90 mm), ACS 
(3.60 ± 1.22 mm, 2.59 ± 1.57 mm) and Emgoain/ACS (3.58 ± 1.58 mm, 
2.98 ± 1.69 mm) groups.
4  | DISCUSSION
The present study has for the first time evaluated the effect of 
Osteogain/ACS on periodontal wound healing/regeneration in 
two- wall intra- bony defects in non- human primates. The use of 
Osteogain/ACS in conjunction with reconstructive surgery resulted 
F IGURE  4 Photomicrographs of two- wall intra- bony defects treated with Emdogain/ACS. (a) A well- healed two- wall intra- bony defects in 
the incisor site. Overview. (Bar: 1 mm; Azan- Mallory staining) (b) Higher magnification of the coronal framed area in (a). (Bar: 100 μm; Azan- 
Mallory staining). (c) A poorly healed two- wall intra- bony defects in the pre- molar site. Overview. (Bar: 1 mm; Azan- Mallory staining) (d) Higher 
magnification of the coronal framed area in (c). (Bar: 100 μm; Azan- Mallory staining). NB, new bone; NC, new cementum; PDL, periodontal 
ligament; JE, junctional epithelium; CT, connective tissue; N, notch (apical extent of root planing); D, root dentin
(a) (b) (c) (d)
F IGURE  5 Representative 
photomicrographs of a two- wall intra- 
bony defects (incisor site) treated with 
Osteogain/ACS. (a) Overview. (Bar: 
1 mm; Azan- Mallory staining). (b) Higher 
magnification of the coronal framed area 
in (a). (Bar: 100 μm; Azan- Mallory staining). 
NB, new bone; NC, new cementum; PDL, 
periodontal ligament; N, notch (apical 
extent of root planing); D, root dentin
(a)
(b)
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in higher amounts of newly formed cementum, periodontal liga-
ment and bone compared to the use of Emdogain/ACS, ACS or OFD 
alone. In both EMD- treated groups (Emdogain/ACS and Osteogain/
ACS), the newly formed periodontal ligament was well vascularized, 
while the collagen fibres inserting in the NC appeared to be denser 
compared to those observed in the OFD and ACS groups, providing 
additional evidence for the positive effect of EMD in promoting peri-
odontal wound  healing. The present results obtained with Emdogain/
ACS are comparable to those reported previously following the use of 
Emdogain demonstrating periodontal regeneration in both animal and 
human intra- bony defects (Ivanovic et al., 2014; Sculean, Chiantella, 
Windisch, & Donos, 2000; Sculean et al., 1999; Sculean, Donos, et al., 
2000; Sculean et al., 2015; Shirakata et al., 2007, 2010).
In the present study, the application of Osteogain/ACS appeared 
to induce periodontal regeneration more consistently than Emdogain/
ACS. This finding is in agreement with our very recent report evalu-
ating the effects of the same treatments on chronic class III furcation 
defects in monkeys (Shirakata et al., 2017). Despite the fact that in 
the mentioned study, none of the treatments achieved complete 
regeneration in class III furcations, the application of Osteogain/
ACS yielded consistently more cementum, periodontal ligament and 
bone compared to the other three treatments (e.g. Emdogain/ACS, 
ACS and OFD). One explanation for the discrepancy in the amount 
of the regenerated tissues between Osteogain/ACS and Emdogain/
ACS may be related to the adsorption of amelogenins in Osteogain/
ACS which was 20%–60% higher compared to that in Emdogain/
ACS as revealed by an ELISA assay. Furthermore, the ACS loaded 
with Emdogain began to degrade in PBS by 3 days, whereas those 
pre- coated with Osteogain showed more stable properties suggest-
ing that in this novel formulation, EMD may be present for a lon-
ger time in the wound area, which in turn may influence the healing 
process (Shirakata et al., 2017). These findings appear to suggest 
that Osteogain/ACS not only maintains a higher concentration of re-
mained and sustained release of amelogenins, but may also provide a 
F IGURE  6 Representative photomicrographs of a two- wall intra- bony defects (pre- molar site) treated with Osteogain/ACS. (a) Overview. 
(Bar: 1 mm; Azan- Mallory staining). (b) Higher magnification of the apical framed area in (a). (Bar: 100 μm; Azan- Mallory staining). (c) Higher 
magnification of the coronal framed area in (a). (Bar: 100 μm; Azan- Mallory staining). NB, new bone; NC, new cementum; PDL, periodontal 
ligament; N, notch (apical extent of root planing); D, root dentin
(a) (b) (c)
TABLE  1 Histomorphometric linear measurement in each group (mean ± SD in mm and (%);n = 3 animals, n = 24 sites; six sites/group
Histometric 
parameters
Treatment modality
OFD ACS Emdogain/ACS Osteogain/ACS
DH (mm) 8.08 ± 2.09 8.09 ± 1.93 8.31 ± 2.30 7.76 ± 2.47
JE in mm and (%) 4.57 ± 0.98 (58.56 ± 15.94) 3.63 ± 1.13 (45.76 ± 14.95) 3.76 ± 1.58 (47.68 ± 18.44) 3.18 ± 1.34 (41.05 ± 15.19)
CT in mm and (%) 0.45 ± 0.42 (5.47 ± 5.02) 0.80 ± 0.67 (9.07 ± 6.28) 1.00 ± 1.33 (10.20 ± 11.62) 0.56 ± 0.78 (5.67 ± 6.53)
NB in mm and (%) 2.64 ± 1.30 (31.90 ± 11.18) 3.08 ± 1.62 (37.79 ± 20.40) 3.63 ± 2.25 (42.28 ± 18.44) 3.89 ± 1.47 (51.61 ± 16.99)
NC in mm and (%) 3.21 ± 1.60 (38.31 ± 13.07) 3.60 ± 1.22 (44.30 ± 10.97) 3.58 ± 1.58 (42.53 ± 14.03) 4.00 ± 1.49 (52.31 ± 15.01)
NA in mm and (%) 1.49 ± 0.90 (19.66 ± 12.04) 2.59 ± 1.57 (31.49 ± 19.56) 2.98 ± 1.69 (34.40 ± 15.78) 3.59 ± 1.65 (46.52 ± 15.17)
DH, defect height; JE, junctional epithelium migration; CT, connective tissue attachment (without cementum); NB, new bone; NC, new cementum; NA, new 
attachment formation.
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more favourable environment for periodontal regeneration compared 
to Emdogain/ACS. Furthermore, they are also in line with findings 
from previous in vitro experiments, which have demonstrated that 
Osteogain significantly increased cell adhesion, proliferation and dif-
ferentiation of osteoblasts when combined with bone grafting parti-
cles or ACS (Miron, Fujioka- Kobayashi, Zhang, Caballé- Serrano, et al., 
2016; Miron, Fujioka- Kobayashi, Zhang, Sculean, et al., 2017) and sig-
nificantly upregulated the expression of genes encoding BMP2 and 
TGF- ß1 while decreasing expression of IL- 1ß (Miron, Chandad, et al., 
2016). Moreover, the differentiation potential of both osteoblasts 
and PDL cells was further retained following the use of Osteogain as 
demonstrated by the increased collagen and osteocalcin gene expres-
sion and significantly higher alizarin red staining (Miron, Chandad, 
et al., 2016).
When interpreting the results, it has to be kept in mind that none 
of the defects in the four treatment groups demonstrated complete 
resolution of the intra- bony component without substantial differ-
ences. These results may, on the one hand, be explained by the limited 
number of included animals/teeth not allowing for appropriate statisti-
cal comparisons and, on the other hand, by the chronic type of defects. 
In this study, non- human primates were chosen as the  anatomical, 
microbiological and immunological features including turnover rate 
of bone remodelling have been shown to be quite similar to those of 
humans (Giannobile, Finkelman, & Lynch, 1994; Oz & Puleo, 2011; 
Pellegrini, Seol, Gruber, & Giannobile, 2009), despite the fact that the 
expenses, demanding maintenance and ethical issues restrict their 
broad use. The rationale to create chronic periodontal defects with 
minimal potential for spontaneous repair was based on previous re-
ports indicating that such defects provide a clinically valuable model 
for evaluating new treatment strategies for periodontal regenerative 
therapy (Caton, Mota, Gandini, & Laskaris, 1994; Giannobile et al., 
1994; Sculean, Donos, et al., 2000).
The rationale for using ACS as a carrier for EMD instead of bone 
grafting materials was based on the fact that ACS is easily applied 
to the variously shaped bone/periodontal defects with moderate 
elasticity (Cochran et al., 2000; Kim et al., 2013; McPherson, 1992; 
Yamashita et al., 2010). Another reason to consider the use of an 
ACS carrier was due to outcomes reported in animals and humans 
demonstrating that following grafting, the healing is frequently 
characterized by persistence of grafting particles either encap-
sulated in connective tissue or surrounded by a bone- like tissue 
(Ivanovic et al., 2014; Kim et al., 2013; Schwarz et al., 2007; Sculean 
et al., 2003, 2015; Shirakata et al., 2010; Yamashita et al., 2010; 
Yoshinuma et al., 2012). These findings indicate that complete re-
generation of the tooth’s supporting tissues is rather inconsistent 
despite the observed clinical improvements (Ivanovic et al., 2014; 
Matarasso et al., 2015; Sculean et al., 2015). The choice of ACS as 
a potential carrier for biologics was additionally supported by very 
recent data from in vitro studies which have shown that the ad-
sorption rate of amelogenin to ACS was higher than those observed 
on NBM, FDBA or a synthetic calcium phosphate material (Miron 
et al., 2015; Miron, Fujioka- Kobayashi, Zhang, Sculean, et al., 2016; 
Stähli et al., 2017). Thus, from a biological point of view, the use of 
collagen constructs aiming at stabilizing the blood clot and serving 
as carriers for biologics such as EMD and growth factors appears to 
represent a potential novel approach to enhance periodontal wound 
healing/regeneration. However, it cannot be excluded that in two- 
wall intra- bony defects, the used ACS did not possess the mechani-
cal properties needed to ensure sufficient wound stability and space 
provision for periodontal regeneration (Kim et al., 2013; Shirakata 
et al., 2017; Susin et al., 2015; Yamashita et al., 2010).
Thus, within their limits, the present findings indicate that in two- 
wall intra- bony defects, reconstructive surgery with Osteogain/ACS 
may represent a potential novel approach for facilitating periodontal 
wound healing/regeneration. Obviously, prior to the clinical use in hu-
mans, additional studies aiming at further investigating the effects and 
the mechanisms of action of Osteogain combined with ACS or with 
various types of bone grafting materials on periodontal regeneration 
are needed.
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